TCGX Acquisition Corp.
No SEC Form 4 filings for $TCGX in the last 30 days.
See all $TCGX insider activity →TCGX closed a $600M Asia Life Sciences Fund I, backed by institutional investors, to invest in biotech across Asia. Biohaven licensed its IgG degrader portfolio to Ono for $200M, including $80M upfront. Roche partnered with Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TCGX (TCGX Acquisition Corp.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Fund close and regional office build suggest increased deal flow and capital availability for Asia biotech investments, but it is not a direct public-market catalyst.
AlphAI scores every news story that mentions TCGX with an AI model for sentiment and relevance, and aggregates insider trades from TCGX Acquisition Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
TCGX closed a $600M Asia Life Sciences Fund I, backed by institutional investors, to invest in biotech across Asia. Biohaven licensed its IgG degrader portfolio to Ono for $200M, including $80M upfront. Roche partnered with Defand Therapeutics to discover molecular glue degraders for cancer and immune diseases.
6 min read
.webp%253Fdisable%253Dupscale%2526width%253D1200%2526height%253D630%2526fit%253Dcrop&w=384&q=75)